England's chickenpox vaccine: what the MMRV evidence shows

Children in England are now offered a chickenpox vaccine for the first time as a routine jab, given as the combined MMRV (measles, mumps, rubella and varicella) vaccine at 12 and 18 months of age from 1 January 2026 [s1][s2]. The evidence behind that decision is solid: pooled trial and field data put a single dose at about 81 percent effective against any chickenpox and roughly 98 percent against moderate or severe disease, with a second dose improving protection against milder cases [s3].

What changed, and why now

The Joint Committee on Vaccination and Immunisation (JCVI) recommended adding varicella vaccine to the routine childhood schedule in a statement dated 14 November 2023, advising two doses at 12 and 18 months [s1]. That reversed a long-standing position. The committee had declined a universal programme in 2009, largely over a theoretical worry about shingles: the concern was that taking circulating chickenpox out of the community would remove the immune "boosting" adults get from exposure to infected children, and could raise shingles cases in middle-aged adults for around 20 years [s1]. JCVI says a long-term study from the United States has since failed to support that theory, which removed the main objection [s1].

Chickenpox is usually mild in children, but "usually mild" is not "always safe." The programme's rationale points to the minority of cases that turn serious — complications including bacterial skin infection, encephalitis (brain inflammation), pneumonitis and, rarely, stroke, with hospitalisation and, in very rare cases, death [s1]. A routine two-dose programme is aimed at that tail of severe outcomes, not just at sparing children an itchy week.

How well the vaccine works

The effectiveness estimates come from a meta-analysis of post-licensure studies in immunocompetent children, which is the closest thing to real-world performance. Pooling those studies, one dose was 81 percent effective against all varicella (95 percent confidence interval 78 to 84) and 98 percent against moderate-to-severe varicella (97 to 99), with the median effectiveness against severe disease reaching 100 percent and the mean 99.4 percent [s3]. The gap between those two numbers is the point: a single dose lets a fraction of vaccinated children still catch a mild, "breakthrough" case, while almost entirely preventing the serious disease that fills hospital beds [s3].

England is a late adopter here, and that is partly why the evidence base is so mature. The pooled estimates draw on post-licensure studies published between 1995 and 2014, a span that covers roughly two decades of routine varicella vaccination in countries that introduced it earlier, notably the United States [s3]. In other words, the programme England began in 2026 rests not on projection but on a long real-world track record of how the vaccine performs once it is given to whole populations of children [s3].

That a single dose is far more effective against moderate-to-severe varicella (98 percent) than against any varicella at all (81 percent) is itself the evidence that the breakthrough cases which slip through are overwhelmingly the mild ones [s3]. The meta-analysis also found no significant difference in single-dose effectiveness by vaccine type or study design, which is reassuring for a programme that will use a combined product across a whole birth cohort rather than the specific vaccines tested in any one study [s3].

Adding a second dose closes much of the remaining gap for mild illness. Pooled two-dose effectiveness against all varicella was 92 percent (95 percent confidence interval 88 to 95), and the meta-analysis found no meaningful difference in effectiveness by vaccine brand or study design [s3]. That is the direct evidence for the two-dose schedule England has adopted, rather than a single shot.

The combination question

Delivering varicella as MMRV rather than a separate injection means it piggybacks on visits and a vaccine platform parents already know, adding chickenpox protection to the existing measles, mumps and rubella coverage at the same two appointments [s2]. The programme's schedule, formulation and catch-up arrangements for children who have fallen behind are set out in the UK Health Security Agency's guidance for practitioners [s2]. For how combined childhood vaccines are built and tested, see how vaccines work.

What to watch

The near-term questions are about uptake and coverage rather than efficacy. England's measles resurgence has shown what happens when MMR coverage slips, as our coverage of why measles spreads so fast and the wider childhood vaccine schedule debate describe; bolting varicella onto the same MMRV visit ties the two programmes' fortunes together. Whether adding the vaccine measurably changes adult shingles rates over the coming decades is the long-run signal researchers will track [s1]. This article is informational and is not medical advice; questions about a child's immunisations should go to a GP or health visitor.